TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00179777|
Recruitment Status : Unknown
Verified July 2017 by Margaret Lawson, Children's Hospital of Eastern Ontario.
Recruitment status was: Active, not recruiting
First Posted : September 16, 2005
Last Update Posted : July 14, 2017
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus, Type 1||Dietary Supplement: hydrolysed infant formula Dietary Supplement: nonhydrolysed infant formula||Not Applicable|
The hypothesis for this study is that weaning to an extensively hydrolyzed infant formula will decrease the incidence of type 1 diabetes in subjects with risk-associated HLA genotypes and a first degree relative with type 1 diabetes, as it does in all relevant animal models for the disease.
I.a: To determine if weaning to a casein hydrolysate infant formula reduces the frequency of diabetes-predictive auto-antibodies in subjects with risk-associated HLA genotype and a first degree relative with type 1 diabetes (mother, father and/or full sibling).
I-b: To determine if weaning to a casein hydrolysate infant formula reduces the frequency of clinical diabetes in subjects with risk-associated HLA genotype and an affected first degree relative.
A secondary aim is to determine relationships between cow's milk antibodies, a measure of cow's milk exposure, and diabetes-associated auto-antibodies.
The mother of the unborn child is recruited during pregnancy. Randomization to one of two infant formulas takes place before birth (after 35 weeks gestation) or immediately after birth.
Experimental Arm: Use of extensively hydrolysed cow's milk based infant formula when needed in supplementation or substitution for breast milk through 6-8 months from birth.
Control Arm: Use of non-hydrolysed cow's milk based infant formula when needed in supplementation or substitution for breast milk through 6-8 months from birth.
All families are encouraged to breast feed their infants for as long as possible. The study infant formula is only used if exclusive breast feeding ceases before 8 months of age.
Cord blood for genotyping is obtained at birth, or failing that from a heel prick by 7 days of age. Only subjects with genotypes indicating increased genetic risk for type 1 diabetes remain in the intervention trial. All other subjects are withdrawn from the study.
All subjects will be followed until the youngest subject turns age 10 years.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||2032 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||TRIGR - Trial to Reduce IDDM in the Genetically at Risk|
|Actual Study Start Date :||March 2002|
|Actual Primary Completion Date :||March 2017|
|Estimated Study Completion Date :||September 2017|
Experimental: Hydrolysed infant formula
Hydrolysed infant formula
Dietary Supplement: hydrolysed infant formula
hydrolysed infant formula
Placebo Comparator: Nonhydrolysed infant formula
Nonhydrolysed infant formula
Dietary Supplement: nonhydrolysed infant formula
nonhydrolysed infant formula
- Type 1 diabetes mellitus assessed by (1) blood glucose and HbA1c at 12 and 18 months of age, and annually from age 2 to 10 years, and (2) oral glucose tolerance test at 6 and 10 years of age. [ Time Frame: 12 and 18 months and annually from 2 years up to 15 years ]glucose and HbA1C; oral glucose tolerance test at 6, 10 years and in the final year of the study
- Diabetes associated islet antibodies (ICA, IAA, GADA, IA-2A) at 3, 6, 9, 12 and 18 months of age, and annually from age 2 to 10 years [ Time Frame: 3, 6, 9, 12, 18 months and annually from 2 years up to 15 years ]diabetes associated antibodies
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00179777
|Principal Investigator:||Hans K Akerblom, MD||University of Helsinki|